疫苗四巨头重返巅峰

医药魔方
11 Mar

长期以来,全球疫苗市场主要被辉瑞、默沙东、GSK和赛诺菲四巨头把持。这样的格局一度被突如其来的新冠疫情所打破。在黑天鹅事件的特定时期,新的玩家得以有机会与四巨头站在同一起跑线上角逐。回过头来看,四巨头在这场竞赛中并未体现出传统优势,也就只有辉瑞可以说是慧眼识珠与BioNTech合作,历史性成就了公司在2022年整体收入突破千亿美元。反观其他三家的表现,可谓差强人意。另一家mRNA疫苗企业...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10